WPD Pharmaceuticals’ WP1220 Drug Demonstrates Median Reduction of 56% in Skin Cancer Lesions in Clinical Trials

Data Presented at the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Feb 2020 VANCOUVER, British Columbia, Feb. 18, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”), a clinical stage pharmaceutical company, in collaboration with license partner, Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq: MBRX) is pleased to announce